Company: BDRX
Filing Date: 2025-11-17
Form Type: POS AM
Source: 0001214659-25-016826
Chunk: 35

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: POS AM
Chunk 35
---
 the warrant subject to applicable securities laws; provided, however, that the May 2023 Placement Agent Warrants are subject to certain
FINRA transfer restrictions. We do not intend to apply for listing of the warrants on any securities exchange or other trading system.

| 19 |

No Rights as Shareholder Until Exercise. Except as set forth in the warrants, the holders of the warrants do not have any voting rights, dividends or
other rights as a holder of our capital stock until they exercise the warrants.

Series E Warrants, December 2023 Private Placement Pre-Funded Warrants and December 2023 Underwriter Warrants

The following is a brief
summary of the Series E Warrants, December 2023 Private Placement Pre-Funded Warrants, the December 2023 Underwriter Warrants, issued
in connection with the with December 2023 Private Placement and December 2023 underwritten public offering, and is subject in all respects
to the provisions contained in the applicable warrants, which are filed as exhibits to our Report on Form 6-K dated December 21, 2023.
Unless otherwise stated, references to warrants in this subsection include the Series E Warrants, the December 2023 Private Placement
Pre-Funded Warrants, and the December 2023 Underwriter Warrants.

Exercisability.
The warrants became exercisable on December 21, 2023. The Series E Warrants and December 2023 Underwriter Warrants expire five years
and three years, respectively from the initial exercise date. The December 2023 Private Placement Pre-Funded Warrants are exercisable
at any time and do not expire. The holder shall deliver the aggregate exercise price for the Depositary Shares specified in the exercise
notice within two trading days following the date of exercise (subject to the ‘cashless exercise’ arrangements described
below).

Cashless Exercise. If,
at the time a holder exercises its Series E Warrants, a registration statement registering the issuance of the securities underlying
the Series E Warrants under the Securities Act is not then effective or available and an exemption from registration under the Securities
Act is not available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to us
upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in
whole or in part) the net number of Depositary Shares determined according to a formula set forth in the Series E Warrants.